These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 27752944)
1. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944 [TBL] [Abstract][Full Text] [Related]
2. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974 [TBL] [Abstract][Full Text] [Related]
3. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914 [TBL] [Abstract][Full Text] [Related]
4. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120 [TBL] [Abstract][Full Text] [Related]
5. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE). Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis. Ohno Y; Tokudome K CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712 [TBL] [Abstract][Full Text] [Related]
7. Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain. Mendoza-Torreblanca JG; García-Cruz ME; Sánchez-Cruz I; Gomez-Gonzalez B; Juárez-Méndez S; Gómez-Lira G Neuroscience; 2019 Nov; 419():108-120. PubMed ID: 31520710 [TBL] [Abstract][Full Text] [Related]
8. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats. Shi J; Zhou F; Wang LK; Wu GF J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the In Vivo Specificity of [ Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A Molecules; 2019 May; 24(9):. PubMed ID: 31052478 [TBL] [Abstract][Full Text] [Related]
10. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204 [TBL] [Abstract][Full Text] [Related]
11. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. Serajee FJ; Huq AM Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053 [TBL] [Abstract][Full Text] [Related]
12. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Gillard M; Fuks B; Leclercq K; Matagne A Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627 [TBL] [Abstract][Full Text] [Related]
13. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465 [TBL] [Abstract][Full Text] [Related]
15. The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance. Stout KA; Dunn AR; Hoffman C; Miller GW ACS Chem Neurosci; 2019 Sep; 10(9):3927-3938. PubMed ID: 31394034 [TBL] [Abstract][Full Text] [Related]
16. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812 [TBL] [Abstract][Full Text] [Related]
17. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673 [TBL] [Abstract][Full Text] [Related]
18. Expression of SV2 isoforms during rodent brain development. Crèvecœur J; Foerch P; Doupagne M; Thielen C; Vandenplas C; Moonen G; Deprez M; Rogister B BMC Neurosci; 2013 Aug; 14():87. PubMed ID: 23937191 [TBL] [Abstract][Full Text] [Related]
19. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357 [TBL] [Abstract][Full Text] [Related]
20. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Janz R; Südhof TC Neuroscience; 1999; 94(4):1279-90. PubMed ID: 10625067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]